Advertisement

Topics

FDA approves BMS' combo for colorectal cancer indication

05:50 EDT 12 Jul 2018 | SmartBrief

The FDA approved Bristol-Myers Squibb's Opdivo, or nivolumab, 3 mg/kg, in combination with low-dose Yervoy, or ipilimumab, 1  -More

Original Article: FDA approves BMS' combo for colorectal cancer indication

NEXT ARTICLE

More From BioPortfolio on "FDA approves BMS' combo for colorectal cancer indication"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...